- Home
- IBG vs PRLD Comparison
IBG vs PRLD Comparison
Compare IBG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- PRLD
- Stock Information
- Founded
- IBG 2018
- PRLD 2016
- Country
- IBG Australia
- PRLD United States
- Employees
- IBG N/A
- PRLD N/A
- Industry
- IBG Beverages (Production/Distribution)
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- IBG Consumer Staples
- PRLD Health Care
- Exchange
- IBG Nasdaq
- PRLD Nasdaq
- Market Cap
- IBG 75.7M
- PRLD 69.1M
- IPO Year
- IBG 2024
- PRLD 2020
- Fundamental
- Price
- IBG $3.38
- PRLD $1.58
- Analyst Decision
- IBG Strong Buy
- PRLD Strong Buy
- Analyst Count
- IBG 1
- PRLD 3
- Target Price
- IBG N/A
- PRLD $4.00
- AVG Volume (30 Days)
- IBG 1.4M
- PRLD 258.3K
- Earning Date
- IBG 11-15-2025
- PRLD 10-31-2025
- Dividend Yield
- IBG N/A
- PRLD N/A
- EPS Growth
- IBG N/A
- PRLD N/A
- EPS
- IBG N/A
- PRLD N/A
- Revenue
- IBG $2,931,243.00
- PRLD $7,000,000.00
- Revenue This Year
- IBG N/A
- PRLD N/A
- Revenue Next Year
- IBG N/A
- PRLD N/A
- P/E Ratio
- IBG N/A
- PRLD N/A
- Revenue Growth
- IBG N/A
- PRLD N/A
- 52 Week Low
- IBG $1.48
- PRLD $0.61
- 52 Week High
- IBG $9.85
- PRLD $1.91
- Technical
- Relative Strength Index (RSI)
- IBG 52.82
- PRLD 57.91
- Support Level
- IBG $3.61
- PRLD $1.49
- Resistance Level
- IBG $4.10
- PRLD $1.72
- Average True Range (ATR)
- IBG 0.44
- PRLD 0.17
- MACD
- IBG -0.11
- PRLD 0.02
- Stochastic Oscillator
- IBG 22.39
- PRLD 75.44
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.